痹祺胶囊口服联合透明质酸钠关节腔内注射对膝骨性关节炎患者膝关节功能及血清COX-2、COMP水平的影响  

Effect of Biqi capsule combined with sodium hyaluronate on knee joint function and serum COX-2 and COMP levels in patients with knee osteoarthritis

作　　者：康玉玲 张江涛 曹蕾 杨澜波[1,2] KANG Yuling;ZHANG Jiangtao;CAO Lei;YANG Lanbo(Luoyang Orthopedic Hospital of Henan Province(Henan Orthopedic Hospital),Luoyang 471000,China;Endoscopy Center of the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南省洛阳正骨医院(河南省骨科医院),河南洛阳471000 [2]河南科技大学第一附属医院内镜中心,河南郑州471000

出　　处：《广东药科大学学报》2020年第6期886-890,902,共6页Journal of Guangdong Pharmaceutical University

基　　金：2019年度河南省中医药科学研究专项课题(2019ZY2080)。

摘　　要：目的探讨痹祺胶囊口服联合透明质酸钠关节腔内注射对膝骨性关节炎患者膝关节功能及血清环氧化酶-2(COX-2)、软骨寡聚基质蛋白(COMP)水平的影响。方法选取我院收治的2016年12月—2018年9月膝骨性关节炎患者106例,随机数字表法分为对照组(n=53)与研究组(n=53)。对照组采取透明质酸钠关节腔内注射,研究组于对照组基础上加用痹祺胶囊,均治疗5周。统计两组临床疗效、治疗前及疗程结束后COX-2及COMP血清含量、膝关节功能(HSS)及疼痛程度(VAS)、病情严重程度(ISOA)、不良反应发生率、疾病复发率。结果(1)临床疗效:研究组总有效率94.34%(50/53)高于对照组81.13%(43/53)(P<0.05);(2)COX-2及COMP血清含量:疗程结束后两组COX-2及COMP血清含量较治疗前降低,且研究组低于对照组(P<0.05);(3)HSS及VAS分值:疗程结束后两组HSS分值较治疗前增高、VAS分值较治疗前降低,且研究组HSS分值高于对照组、VAS分值低于对照组(P<0.05);(4)ISOA分值:疗程结束后两组ISOA分值较治疗前降低,且研究组低于对照组(P<0.05);(5)不良反应:研究组不良反应发生率13.21%(7/53)与对照组7.55%(4/53)比差异无统计学意义(P>0.05);(6)疾病复发率:研究组疾病复发率3.77%(2/53)低于对照组16.98%(9/53)。结论联合采取透明质酸钠关节腔内注射及痹祺胶囊口服治疗膝骨性关节炎,可有效降低COX-2及COMP血清含量,减轻关节疼痛程度及病情严重程度,改善膝关节功能,提高疾病整体治疗效果,降低疾病复发率,且不会增加不良反应发生风险,具有安全性。Objective To investigate the effect of Biqi capsule combined with sodium hyaluronateon knee joint function and serum cyclooxygenase-2(COX-2)and cartilage oligomeric matrix protein(COMP)in patients with knee osteoarthritis.Methods A total of 106 patients with knee osteoarthritis in our hospital from December 2016 to September 2018 were randomly divided into the control group(n=53)and the study group(n=53).The control group was given intra-articular injection of sodium hyaluronate,and the study group was treated with Biqi capsules on the basis of the control group,and both were treated for 4 weeks.The clinical efficacy,serum COX-2 and COMP levels,knee function(HSS)and pain(VAS),severity of disease(ISOA),the incidence of adverse reactions and disease recurrence rates before and after treatment in two groups were measured.Results(1)Clinical efficacy:The total effective rate of the study group was 94.34%(50/53)higher than that of the control group(81.13%,43/53)(P<0.05).(2)COX-2 and COMP serum content:After the end of the treatment,the serum levels of COX-2 and COMP were lower in two groups than that before treatment,and the levels of COX-2 and COMP were lower in the study group than that of the control group(P<0.05).(3)HSS and VAS scores:After the treatment,the HSS scores were higher than that before treatment,and the VAS scores were lower than that before treatmentin both groups.The HSS scores in the study group were higher than that of the control group,but the VAS scores were lower than that of the control group(P<0.05).(4)ISOA scores:After the treatment,the ISOA scores in the two groups were lower than that before treatment,and the study group was lower than the control group(P<0.05).(5)Adverse reactions:There was no significant difference between the study groups adverse reaction rate(13.21%;7/53)and the control group(7.55%,4/53)(P>0.05).(6)Disease recurrence rate:The disease recurrence rate was 3.77%(2/53)in the study group lower than that of the control group(16.98%,9/53).Conclusion The combined treatment of

关 键 词：痹祺胶囊 透明质酸钠 关节腔内注射 膝骨性关节炎 膝关节功能 COX-2 COMP 

分 类 号：R969.4[医药卫生—药理学] R982[医药卫生—药学]